Thyrocare Technologies logo

THYROCARE - Thyrocare Technologies Share Price

₹916.5 1.7  0.2%

Last Trade - 7:46am

Mid Cap
Market Cap £473.3m
Enterprise Value £465.5m
Revenue £44.0m
Position in Universe 418th / 3097
Unlock THYROCARE Revenue
Relative Strength (%)
1m -0.74%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1,830 2,410 3,044 3,563 4,029 4,332 4,935 5,835 +18.8%
+10.0 +6.1 +56.1 -5.1 +10.7 +21.2 +35.3
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 December 2020,Thyrocare Technologies Ltd revenues increased 5% toRS3.48B. Net income decreased 16% to RS756.7M. Revenuesreflect Diagnostic Testing Services segment increase of 10%to RS3.34B. Net income was offset by Employee benefitexpense increase of 12% to RS395.4M (expense), Otherexpenses increase of 5% to RS687.6M (expense). Dividend pershare totaled to RS10.00.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for THYROCARE
Graphical History


THYROCARE Revenue Unlock THYROCARE Revenue

Net Income

THYROCARE Net Income Unlock THYROCARE Revenue

Normalised EPS

THYROCARE Normalised EPS Unlock THYROCARE Revenue

PE Ratio Range

THYROCARE PE Ratio Range Unlock THYROCARE Revenue

Dividend Yield Range

THYROCARE Dividend Yield Range Unlock THYROCARE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
THYROCARE EPS Forecasts Unlock THYROCARE Revenue
Profile Summary

Thyrocare Technologies Limited is an India-based healthcare service provider. The Company operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The Company offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The Company offers cancer diagnosis and water testing through its brands Nueclear and Whaters, respectively. The Company tests cover varied age groups from offerings for prenatal screening, to screening for hormonal imbalance, nutritional deficiencies and tracking lifestyle disorders.

Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated January 28, 2000
Public Since May 9, 2016
No. of Shareholders: 36,037
No. of Employees: 1,333
Sector Healthcare
Industry Healthcare Providers & Services
Exchange National Stock Exchange of India
Shares in Issue 52,874,055
Free Float (0.0%)
Eligible for
THYROCARE Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for THYROCARE
Upcoming Events for THYROCARE
Frequently Asked Questions for Thyrocare Technologies
What is the Thyrocare Technologies share price?

As of 7:46am, shares in Thyrocare Technologies are trading at ₹916.5, giving the company a market capitalisation of £473.3m. This share price information is delayed by 15 minutes.

How has the Thyrocare Technologies share price performed this year?

Shares in Thyrocare Technologies are currently trading at ₹916.5 and the price has moved by 53.28% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Thyrocare Technologies price has moved by 15.73% over the past year.

What are the analyst and broker recommendations for Thyrocare Technologies?

Of the analysts with advisory recommendations for Thyrocare Technologies, there are there are currently 1 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Thyrocare Technologies is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Thyrocare Technologies next release its financial results?

Thyrocare Technologies is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Thyrocare Technologies dividend yield?

The Thyrocare Technologies dividend yield is 1.64% based on the trailing twelve month period.

Does Thyrocare Technologies pay a dividend?

Last year, Thyrocare Technologies paid a total dividend of 15, and it currently has a trailing dividend yield of 1.64%. Looking ahead, Thyrocare Technologies has not announced an ex-dividend date yet.

When does Thyrocare Technologies next pay dividends?

Thyrocare Technologies has yet to annouce their ex-dividend date. The historic dividend yield on Thyrocare Technologies shares is currently 1.64%.

How do I buy Thyrocare Technologies shares?

To buy shares in Thyrocare Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Thyrocare Technologies?

Shares in Thyrocare Technologies are currently trading at ₹916.5, giving the company a market capitalisation of £473.3m.

Where are Thyrocare Technologies shares listed? Where are Thyrocare Technologies shares listed?

Here are the trading details for Thyrocare Technologies:

Country of listing: India
Exchange: NSI
Ticker Symbol: THYROCARE
What kind of share is Thyrocare Technologies?

Based on an overall assessment of its quality, value and momentum, Thyrocare Technologies is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Thyrocare Technologies share price forecast 2021?

Shares in Thyrocare Technologies are currently priced at ₹916.5. At that level they are trading at 5.94% discount to the analyst consensus target price of 0.00.

Analysts covering Thyrocare Technologies currently have a consensus Earnings Per Share (EPS) forecast of 21.192 for the next financial year.

How can I tell whether the Thyrocare Technologies share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Thyrocare Technologies. Over the past six months, the relative strength of its shares against the market has been -7.75%. At the current price of ₹916.5, shares in Thyrocare Technologies are trading at 10.41% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Thyrocare Technologies PE Ratio?

The Thyrocare Technologies PE ratio based on its reported earnings over the past 12 months is 61.82. The shares are currently trading at ₹916.5.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Thyrocare Technologies?

Thyrocare Technologies's management team is headed by:

Amruta Velumani - CHM
A. Sundararaju - CFO
Sumathi Velumani - NED
Gopal Hegde - NID
Vishwas Kulkarni - NID
Neetin Desai - NID
Caesar Sengupta - OTH
M. Chandrasekhar - GMG
Sachin Salvi - GMG
M. Santhosh - GMG
Ramjee Dorai - GCN
S. Krishnakumar - OTH
Rajkumar Kushawaha - OTH
Indumati Gopinathan - NED
Arindam Haldar - CEO
Who are the major shareholders of Thyrocare Technologies?

Here are the top five shareholders of Thyrocare Technologies based on the size of their shareholding:

Velumani (A.) Individual Investor
Percentage owned: 28.02% (14.8m shares)
Thyrocare Publication Pvt.Ltd. Corporation
Percentage owned: 12.36% (6.53m shares)
Thyrocare Properties And Infrastructure Pvt. Ltd. Corporation
Percentage owned: 9.88% (5.23m shares)
Nalanda India Equity Fund Ltd. Corporation
Percentage owned: 7.23% (3.82m shares)
Sundararaju (A) HUF Individual Investor
Percentage owned: 4.57% (2.42m shares)
Similar to THYROCARE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.